Cervomed announces oral presentation at ctad 2023 highlighting phase 2b neflamapimod program for the treatment of patients with dementia with lewy bodies

Oral neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health and slow or prevent disease progression, which would make it the first disease-modifying treatment in dlb phase 2b rewind-lb study underway; completion of enrollment planned in 1h 2024, and topline primary efficacy results in expected in 2h 2024 boston , oct. 18, 2023 /prnewswire/ -- cervomed inc. (nasdaq: crvo), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will present deeper insights highlighting the neflamapimod clinical development program, including findings in phase2a that led to the final phase 2b study design for the treatment of patients with dementia with lewy bodies (dlb), in an oral presentation at the 16th clinical trials in alzheimer's disease (ctad) conference, being held october 24-27, 2023, in boston, massachusetts. "we are pleased to have the opportunity to comprehensively present the findings in phase 2a and discuss the analyses that went into optimizing the phase 2b study design for the treatment of patients with dlb at the upcoming ctad conference," said john alam, md, chief executive officer of cervomed.
CRVO Ratings Summary
CRVO Quant Ranking